PT-141 (Bremelanotide) (10 mg Vial) Dosage Protocol
PT-141 is a melanocortin receptor agonist (MC3R/MC4R) studied for sexual arousal and erectile function. Acts via the central nervous system rather than vascular mechanisms.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once daily (titration protocol) or PRN before activity | Half-life: ~2 hours; effects 6–12 hours
Standard Approach (3 mL = 3.33 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 3.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Weeks 1–8 (titration) | 500 mcg | 15 units | 0.15 mL | 20 doses |
| Weeks 9–12 | 1 mg | 30 units | 0.30 mL | 10 doses |
| Weeks 13–16 | 1.5 mg | 45.0 units | 0.45 mL | 6 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 1 mg per dose, once daily (titration protocol) or prn before activity (7 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| PT-141 (Bremelanotide) (10 mg) vials | 6 vials | 9 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 2 × 10 mL | 3 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
PT-141 (bremelanotide) is dosed PRN (as-needed) for sexual arousal/erectile function research. Unlike PDE5 inhibitors (sildenafil) which work peripherally, PT-141 acts centrally — effects begin in the brain and spread to peripheral sexual response.
Maximum once per 24 hours due to receptor desensitization. The 6–12 hour effect window means dosing 30–45 min before desired effect typically suffices.
Dosing Protocol
Titration schedule (subcutaneous, daily during titration; PRN after target):
- Weeks 1–8 (titration): 500 mcg per dose.
- Weeks 9–12: 1.0 mg per dose.
- Weeks 13–16 (target): 1.5 mg per dose. Research max — do not exceed.
Timing: Inject 30–45 minutes before desired effect. Effects last 6–12 hours.
Frequency limit: Maximum 1 dose per 24 hours.
Nausea management: Pre-treat with ondansetron 4 mg oral 30 minutes before injection if nausea-prone (~40% of trial subjects experience nausea).
No cycle structure — PRN use only.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
PT-141 is a cyclic heptapeptide analog of α-MSH. It activates melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus and limbic system, producing sexual motivation and arousal centrally.
The mechanism distinguishes PT-141 from PDE5 inhibitors (sildenafil/tadalafil) which work peripherally on vascular smooth muscle. PT-141 can produce desire and arousal even without physical stimulation.
Potential Benefits & Side Effects
Potential Benefits
- Studied for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Phase 2/3 trials in males with erectile dysfunction.
- CNS mechanism distinct from vascular PDE5 inhibition.
- Effects last 6–12 hours from a single dose.
Side Effect Profile
- Nausea (most common — ~40% in trials).
- Flushing, headache.
- Transient hypotension.
- Pre-treatment with ondansetron 4 mg oral 30 min prior reduces nausea.
Lifestyle Factors
- Inject 30–45 minutes before desired effect.
- Maximum once per 24 hours.
- Pre-treatment with antiemetic for first few uses if nausea-prone.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- 90° angle with short insulin needle.
- Bring to room temperature before injecting.